DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Lansigan Frederick; Nakamura Ryotaro; Quick Donald P.; Vlock Daniel; Raubitschek Andrew; Gillies Stephen D.; Bachanova Veronika

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

【24h】

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

机译：Di-Leu16-IL2，一种抗CD20-白细胞介素-2免疫细胞因子，在复发和难治性B细胞淋巴瘤的患者中是安全和活跃的：最大耐受剂量，最佳生物剂量和推荐2剂量的报告

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Lansigan Frederick; Nakamura Ryotaro; Quick Donald P.; Vlock Daniel; Raubitschek Andrew; Gillies Stephen D.; Bachanova Veronika;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose [J] . Lansigan Frederick, Nakamura Ryotaro, Quick Donald P., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Di-Leu16-IL2，一种抗CD20-白细胞介素-2免疫细胞因子，在复发和难治性B细胞淋巴瘤的患者中是安全和活跃的：最大耐受剂量，最佳生物剂量和推荐2剂量的报告
2. The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study [J] . OConnor Owen A., Gerecitano John, Van Deventer Henrik, Leukemia and lymphoma . 2015,第9期

机译：粒细胞集落刺激因子的加入改变了剂量限制性毒性，并显着增加了复发或难治性淋巴瘤患者驱动蛋白纺锤体蛋白抑制剂SB-743921的最大耐受剂量和活性：一项国际，多中心的I / II期研究结果
3. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study [J] . Stathis Anastasios, Flinn Ian W., Madan Sumit, Investigational new drugs. . 2018,第5期

机译：IMGN529的安全性，耐受性和初步活性，CD37靶向抗体 - 药物缀合物，复发或难治性B细胞非霍奇金淋巴瘤的患者：一种剂量升级，我研究
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Safety tolerability and preliminary activity of IMGN529 a CD37-targeted antibody-drug conjugate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation phase I study [O] . Anastasios Stathis, Ian W. Flinn, Sumit Madan, -1

机译：IMGN529（一种靶向CD37的抗体-药物偶联物）在复发性或难治性B细胞非霍奇金淋巴瘤患者中的安全性耐受性和初步活性：剂量递增I期研究
7. Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [O] . Winter, Jane N., Inwards, David J., Spies, Stewart, 2009

机译：Yttrium-90 Ibritumomab Tiuxetan剂量经计算可向关键器官提供高达15 Gy的剂量，可与高剂量BEAM和自体移植安全地联合用于复发性或难治性B细胞非霍奇金淋巴瘤

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

著录项

相似文献

相关主题

期刊订阅